Endogenous Extracellular Matrix Regulates the Response of Osteosarcoma 3D Spheroids to Doxorubicin.
Margherita CortiniFrancesca MacchiFrancesca ReggianiEmanuele VitaleMaria Veronica LipreriFrancesca PerutAlessia CiarrocchiNicola BaldiniSofia AvnetPublished in: Cancers (2023)
The extracellular matrix (ECM) modulates cell behavior, shape, and viability as well as mechanical properties. In recent years, ECM disregulation and aberrant remodeling has gained considerable attention in cancer targeting and prevention since it may stimulate tumorigenesis and metastasis. Here, we developed an in vitro model that aims at mimicking the in vivo tumor microenvironment by recapitulating the interactions between osteosarcoma (OS) cells and ECM with respect to cancer progression. We long-term cultured 3D OS spheroids made of metastatic or non-metastatic OS cells mixed with mesenchymal stromal cells (MSCs); confirmed the deposition of ECM proteins such as Type I collagen, Type III collagen, and fibronectin by the stromal component at the interface between tumor cells and MSCs; and found that ECM secretion is inhibited by a neutralizing anti-IL-6 antibody, suggesting a new role of this cytokine in OS ECM deposition. Most importantly, we showed that the cytotoxic effect of doxorubicin is reduced by the presence of Type I collagen. We thus conclude that ECM protein deposition is crucial for modelling and studying drug response. Our results also suggest that targeting ECM proteins might improve the outcome of a subset of chemoresistant tumors.
Keyphrases
- extracellular matrix
- induced apoptosis
- small cell lung cancer
- type iii
- cancer therapy
- squamous cell carcinoma
- papillary thyroid
- cell cycle arrest
- mesenchymal stem cells
- bone marrow
- squamous cell
- single cell
- emergency department
- wound healing
- young adults
- cell proliferation
- signaling pathway
- cell death
- cell therapy
- binding protein
- umbilical cord
- small molecule
- protein protein